Over 90% of the 156 respondents (predominantly vets, but also managers) believed CT was important in first opinion practice, but nearly half did not have access to a scanner.
25% said they were interested in buying a CT scanner, mainly for the improved diagnostics and desire to keep more cases in-house.
The main reasons for not buying a CT scanner were: space, cost and lack of confidence.
Matt Winter, radiologist and CVMO at VetCT said: “Imaging in first opinion practice is evolving rapidly with innovations in veterinary-specific CT technology, modern machines are more available and affordable than ever.
"We need to build confidence through training and understanding of the technology, and the comprehensive support available to practices.”
While practices with a CT scanner felt they were using it optimally for the most part, specialist radiologist reporting emerged as the most significant factor towards optimising its use.
However, a third of respondents not currently using teleradiology (the remote reporting by specialist radiologists of diagnostic images acquired by a practice), said they did not know enough about it and/or hadn’t considered it.
Matt said: “Expert teleradiology to support with image interpretation is enabling more practices than ever to offer advanced imaging and provide state-of-the-art diagnostics for patients, meeting growing client expectations, elevating patient care and improving outcomes."
VetCT’s webinars on CT optimisation are available on Youtube: https://www.youtube.com/c/Vetctspecialists
Avishield IB G1-13 is indicated for active immunisation of chicks to reduce the adverse effect on cilia caused by infectious bronchitis.
The vaccine is one of two targeting the IBV 793B serotype and, with the addition of this new claim, Avishield can now be administrated on broiler, broiler breeder and laying hen farms.
Avishield IB GI-13 is a lyophilisate for oculonasal suspension/use in drinking water which contains live avian infectious bronchitis virus variant strain V-173/11: 102.7-104.6 EID50.
It has an onset of immunity 10 days after vaccination and a duration of immunity of 56 days.
Johnny Wells West, poultry key account manager at Dechra Veterinary Products, said: “The new licence extension for Avishield IB G1-13 allows greater flexibility for poultry producers to protect their flocks against infectious bronchitis on broiler, broiler breeder and laying hen farms and it is welcome news for both Dechra and the poultry industry.”
For more information contact Johnny Wells West on 07584 175758 or visit http://www.dechra.co.uk/Avishield IB G1-13
The survey of 97 cat owners and 156 vets conducted in June last year found that currently only 30% of cat owners give supplements to their cat but 74% would be willing to try them.
The survey also found that whilst 80% of vets thought the main reasons to be hesitant about recommending feline supplements were palatability and the owner’s ability to give products, owners were less concerned about the ease of giving the supplement (53%), and more concerned about the cost (45%) and being unsure of the benefits (39%).
Tara Evans RVN, head of sales at Vita, said: “It is interesting that the majority of vets believe that practicalities around administering oral supplements is the main drawback to giving these products, whereas only 53% of owners were concerned about this.
"Understanding owner concerns regarding efficacy and price could help vets support more owners to move forward with supplements for their cats.”
According to the survey, the most frequently used supplements, by both vets and owners are those made to support joints.
Cat owners also showed an interest in giving supplements for general wellness (61%).
Tara added: “Owners are open to supplementing for general health, as well as more specific health-related issues.”
www.vitaanimalhealth.com
The hearing took place in Mr Prichard's absence after he failed to respond to Colleges attempts to contact him, including by email, post, telephone and personal service of documents.
However, in its decision to proceed in Mr Prichard’s absence, the Committee confirmed that it would not hold his non-attendance against him or attach any adverse inference to that fact.
Mr Prichard was charged with taking quantities of the controlled, prescription-only drug Vetergesic from the practice’s stock other than for legitimate veterinary use.
He was further charged that he took Vetergesic from the practice by drawing it into a syringe for the purposes of self administration, and that in doing so, his conduct was dishonest.
In another set of charges, it was alleged that on five separate occasions, Mr Prichard had attended the practice to work as a veterinary surgeon whilst unfit to do so.
The final charge related to Mr Prichard’s failure to respond adequately or at all to all reasonable requests from the RCVS for his response to concerns raised about his conduct.
At the beginning of the hearing Nicole Curtis, acting on behalf of the College, read the written evidence from 11 separate witnesses outlining the facts related to the charges against Mr Prichard, including the record of an investigative meeting held by the practice in which he admitted his theft and use of the controlled drug and following which, he was dismissed from his employment.
The Committee found all the charges proven and then considered whether they amounted to serious professional misconduct.
In terms of aggravating factors the Committee found that there was a risk of injury, recklessness, premeditated and sustained misconduct, and that there was an abuse of his professional position in accessing prescription-only controlled drugs for reasons other than legitimate veterinary use.
In mitigation, the Committee considered that he had made admissions as part of the practice’s internal disciplinary investigation.
Overall, the Committee found he had breached aspects of the Code of Professional Conduct related to honesty and integrity, making animal health and welfare his first priority, appropriate use of veterinary medicines, taking steps to address physical and mental health conditions that could affect fitness to practise, responding to reasonable requests from the RCVS, and bringing the profession into disrepute.
Therefore, the Committee found him guilty of serious professional misconduct in relation to all of the charges charges.
The Committee felt that, considering the seriousness of the misconduct, removal from the Register was the most appropriate decision.
Austin Kirwan, chairing the Committee and speaking on its behalf, said: “This is a case involving serious dishonesty, sustained over a period of time, and conduct potentially detrimental to animal welfare, as well as wilful disregard of professional regulations.
“Regrettably, Mr Prichard’s failure to engage with the College and with the regulatory process limited the options open to the Committee.
"Notwithstanding this, Mr Prichard’s disgraceful conduct is so serious that removal from the Register is the only means of protecting animals and the wider public interest which includes the maintenance of public confidence in the profession and the upholding of standards.”
www.rcvs.org.uk/disciplinary
The acquisition of Jurox brings Zoetis a valuable animal health portfolio, including Alfaxan, a leading anaesthetic product for companion animals and high-quality local R&D and manufacturing operations in Australia.
Stephanie Armstrong, Senior Vice President and Cluster Lead UK, BeNeLuX, Nordics & Ireland, said: “We are grateful to the O’Brien family for entrusting the future of this family-owned business to Zoetis.
"Jurox’s portfolio plays to the strengths of our core business and will be a complementary fit with the solutions we deliver to veterinary professionals, livestock producers and pet owners.
"With Zoetis’ global sales and regulatory expertise in more than 45 direct markets, we look forward to expanding the impact and reach of the entire Jurox portfolio here in the UK and Ireland.”
www.jurox.com
The company says the workshop will provide vets with an opportunity to extend their knowledge of Q Fever, a zoonotic disease that not only affects reproductive performance and productivity in cattle but also presents a health threat to farmers, farming families and related professions such as vets, veterinary technicians and abattoir workers.
The workshop will be presented by Raphaël Guatteo (pictured right), Professor in Bovine Medicine and Health Management at the Veterinary College of Nantes (Oniris) in France.
Raphaël will share his wealth of knowledge on Q Fever including his extensive research into the disease.
He'll answer any questions that delegates may have about Q Fever and will discuss case studies, diagnostic challenges and the importance of quick diagnosis, treatment options and prevention through vaccination.
The Q Fever workshop will take place between 4.00pm and 5.30pm on Thursday 20 October in the Shorthorn Room at the Hilton Metropole in Birmingham.
The workshop is free of charge, but spaces are limited.
Under the previous system, complaints made about a veterinary surgeon or veterinary nurse would, at Stage One, be considered by a Case Examiner Group (CEG) which would determine if there was an arguable case of serious professional misconduct.
If the CEG found there was an arguable case, it would then refer it to Stage Two of the process for consideration by the Preliminary Investigation Committee.
The CEG stage of the process has now been replaced by Stage One Preliminary Investigation Committees which, rather than using the ‘arguable case’ threshold, will consider from the outset whether there is a realistic prospect that the alleged conduct constitutes serious professional misconduct and that there is sufficient evidence.
The new Stage One Preliminary Investigation Committees will comprise members of the professions and lay people, and will be assisted in their investigations by an RCVS Case Manager who will also be the first point of contact for those raising concerns, witnesses and respondents in the case.
Eleanor Ferguson, RCVS Registrar and Director of Legal Services, said: “By keeping to one consistent threshold for serious professional misconduct throughout the concerns investigation process, we hope that these changes will help to simplify our investigations while still ensuring that the process remains robust and thorough.
"We also hope that, in time and when the changes are fully bedded in, we may also see a swifter resolution to some cases, as concerns that may previously been referred on to Stage Two of the process can now be closed at Stage One.”
If a Stage One Preliminary Investigation Committee cannot close a case it will refer it on to a Stage Two Preliminary Investigation Committee.
This will gather additional information and evidence and then determine if there is a realistic prospect of finding serious professional misconduct and if it is in the public interest for the case to go to Stage Three - a full, public Disciplinary Committee hearing.
Eleanor added: “The introduction of these new stages is the first step in the programme of reform of our concerns investigation and disciplinary processes.
"Next year we will be looking to introduce our Charter Case Protocol which will be a way of resolving some less serious cases of alleged misconduct where it would not necessarily be in the public interest to hold a full Disciplinary Committee hearing.”
www.rcvs.org.uk/concerns
Nutrafibre contains high fibre pellets which use a combination of insoluble and soluble plant fibres, probiotic & prebiotics and fish hydrolysate which, the company says, optimises stool consistency and encourages normal bowel movements.
The company claims Nutrafibre also assists anal gland clearance, helps maintain a sufficient level of fibre in the body, supports pets with sensitive digestion, helps reduce hairball in cats and also helps to balance raw and high meat content diets.
Chris Jones, Director at Nutravet said: “We’re incredibly excited to launch this innovative new fibre product.
"The team have worked in partnership with veterinary practices across the UK to create this high fibre supplement and the feedback has been incredibly positive from both vets and pet owners alike.”
For more information, contact: 0845 604 1688, email: info@nutravet.co.uk or visit www.nutravet.com.
The guide, which was first published in 2020, is designed to help veterinary professionals give pet owners sound, independent advice about what to feed their animals.
The guide originally launched with factsheets for both veterinary professionals and pet owners about commercially manufactured, grain-free, raw and home-prepared cooked diets.
The new factsheets cover:
The new factsheets build on considerations for feeding healthy dogs and cats by providing information on the formulation of diet types for pets under veterinary care and those with even more specific nutritional requirements.
The new BSAVA Guide to Nutrition cost £40, reduced to £26 for BSAVA members from: https://www.bsavalibrary.com/
The survey, which is being conducted in partnership with Hazlewoods accountants, will be used to provide anonymised benchmarking information to enable vets to compare their practice profitability and help identify areas where profitability could be improved.
The survey asks questions around a range of reporting figures including gross profit margin, staffing cost levels and EBITDA (Earnings before interest, taxes, depreciation, and amortisation), to allow for benchmarking in greater detail.
The anonymised benchmarking results of the survey will be free to all participants, including non SPVS members.
SPVS members will receive the benchmarking results together with supporting commentary.
The deadline for completion is 4th November 2022.
https://spvs.org.uk/spvs-profitability-survey
As part of the redevelopment, kennel capacity will increase from 107 to 197, there'll be a new emergency and critical care hub, sixteen new consult rooms and a new imaging suite with MRI and CT scanners, two ultrasounds and two X-ray machines.
There will also be a 66-seat seminar room.
Work is expected to be completed early next year, and the practice will be recruiting for around 75 new team members to service the expanded centre.
Simon Tappin, clinical director at DWR, said: “This long-awaited expansion will transform our practice, offering even more space and capacity for referrals, brand-new equipment and a seamless experience for our clients.
“It will also bolster our reputation as a training practice, with the expansion of our intern and residency programmes adding to our already-impressive provision in this area."
The practice is also implementing case management changes, with a single point of contact for every client and individual case managers in every discipline.
The traditional reception area is being replaced with a concierge greeting service for clients, with staff on hand to book them in on iPads.
Client care team manager Deborah Bell said: “This is a USP for us and we think it’s an industry first. The idea came from how medical secretaries work in human health.
“When a referring vet calls us, our client care team takes the basic details and passes them on to the case manager for that discipline. They will contact the client, make appointments and meet the client in person on arrival.
“We have 12 case managers for our disciplines at the moment, with the potential to expand. As well as providing a personalised service for our clients, it provides great career progression opportunities for our client care team.”
www.dickwhitereferrals.com
Suprelorin 4.7mg is a sustained release implant containing deslorelin (a GnRH super agonist) which has been EMA and VMD approved for use in male cats from 3 months of age.
The implant provides temporary infertility and suppression of urine odour and of sexual behaviours such as libido, vocalisation, urine marking, and aggressiveness in intact male cats.
The implant typically lasts for at least 12 months1.
Virbac says that in most cats, testosterone levels drop within 2 weeks after implantation, followed by reduced testicular volume and reduced size of penile spines from weeks 4-8 after implantation.
Sexual behaviours begin to decrease within a week after treatment, starting with reduced vocalisation, followed by reduction in libido, urine odour, urine marking, and aggressiveness from 4 weeks after implantation.
Induction of infertility is achieved from approximately 6 weeks.
Dr Neil Mottram MRCVS, Technical Product Manager at Virbac said: "The ability to use Suprelorin in male cats provides an opportunity for practices to offer a choice when it comes to neutering, and to tailor their recommendations to meet the individual needs of both the cat and the client.
"Suprelorin provides an ideal solution for cats where the client wants the benefit of surgery without the permanent loss of fertility, where there is an anaesthetic risk in high value kittens or where there is benefit to allow enough time between neutering, vaccination and homing to minimise stress".
The implant is inserted subcutaneously, under the loose skin on the back between the lower neck and the lumbar area.
Virbac says implantation is a quick procedure and does not require anaesthesia or hospitalisation, which can be of particular benefit in practices facing pressures on surgical waiting lists.
Suprelorin 4.7mg has also received a licensed claim in pre-pubertal female dogs for the induction of temporary infertility to delay the first oestrus and heat signs, and to prevent pregnancy at a young age in intact and healthy sexually immature female dogs.
The implant should be administered between 12 and 16 weeks of age.
For more information, talk to your Virbac Territory Manager or the Virbac Technical Team on 01359 243243.
Nutraflex contains turmeric curcumin complex and boswellia extract, which Nutravet says work synergistically to support the natural systems that control inflammation.
The new product also contains glucosamine, a structural component of cartilage, and chondroitin sulphate to help maintain synovial fluid viscosity.
Nutravet claims the new product is fast acting, soothes stiff joints, aids long-term mobility, flexibility and joint structure, and supports the natural systems that control inflammation.
Chris Jones, Director at Nutravet said: “We’re delighted to be adding Nutraflex to our market-leading range of natural health products for pets.
"We’re always looking at ways of improving our products and Nutraflex provides our authorised stockists with a high strength veterinary exclusive joint support, supported by independent trial data, which works quickly to ultimately help pets that are suffering with joint stiffness.”
Nutraflex is available to order exclusively to authorised veterinary practices.
For more information, contact Nutravet on 0845 604 1688, email info@nutravet.co.uk or visit www.nutravet.com.
The book includes interviews with researchers and thought leaders, including Professor Jeff French, Hugues Ruault du Plessis and Professor Thomas Webb.
There's a chapter on ways to influence owner behaviour, an explanation of the ways in which we make decisions and a description of the COM-B model (Capability, Opportunity, Motivation – Behaviour), which Professor Webb argues can be applied to help manage pet obesity, the advantage being that it: “….recognises the importance of motivation, but suggests that people also need to be and feel capable of taking action and have the opportunity to do so.”
Also included are clinical research summaries and practical tips to help communication around these issues in practice.
Purina’s Scientific Affairs Manager for the UK and Ireland, Libby Sheridan, said: “Pet obesity is a challenge that veterinary teams face every day, with six in ten dogs and cats overweight or obese, making obesity one of the most common medical conditions in pets worldwide.1,2
"This e-book delivers a thought-provoking new take on pet obesity which I hope will inspire teams in veterinary practices to adopt innovative approaches to support their clients and achieve positive outcomes for their patients.”
The e-book is suitable for all members of the veterinary team who are involved in weight management clinics or have an interest in developing new strategies to better communicate with and support pet owners.
Download book here.
References
The researchers say the effectiveness of cheaper devices could result in wider use amongst farmers, vets and hoof trimmers helping to identify lameness earlier.
The study, led by RVC undergraduate veterinary student, Aidan Coe, alongside Dr Nicola Blackie, a senior lecturer in Production Animal Science at the RVC, compared the thermal images of 83 cows’ hind feet, captured with both high and low cost thermal imaging devices.
Very little difference was identified in the performance and quality of the devices despite the low-cost device being 2% the cost of the high cost device.
Images captured suggested that low-cost thermal imaging devices would be the most cost-effective choice to aid in the identification of lameness.
This study highlights the effectiveness of cheaper infrared thermal imaging devices in identifying the condition which has the potential to lead to the wider use of the devices by farmers, vets and hoof trimmers, in turn allowing the condition to be identified earlier.
Whilst high-cost devices have sometimes been used to detect lameness in cattle, the price point of up to £20,000 and fragility has previously limited their usefulness in a farm setting.
Aidan Coe, Undergraduate Veterinary Student at the RVC, and lead researcher on this paper, said: “There is a possibility that low-cost infrared thermal imaging devices could be used as an objective, cost-effective method of assessing the lameness of the national herd, which may prove a useful adjunct to the current lameness detection methods.”
The full paper can be accessed at: https://www.mdpi.com/2306-7381/9/8/414
Reference
A paper introduced by the RCVS Registrar Eleanor Ferguson looked at the possibility of the RCVS prosecuting, for example, unqualified individuals undertaking veterinary work and courses falsely purporting to lead to a registerable qualification.
The paper also explored other options, including better educating animal owners about veterinary services and assisting people with concerns about the breaches of the VSA to raise them with the authorities.
Council heard that over the past year, the RCVS had assisted other agencies on investigations of suspected VSA breaches on a number of occasions.
It was considered that the RCVS could consider undertaking its own private investigations and criminal prosecutions when statutory prosecuting authorities did not have the resources to pursue these cases.
However, the RCVS has no statutory powers of investigation, so if it did pursue a private prosecution, it would have no powers to carry out a criminal investigation or compel evidence.
Council members voted for a further paper setting out a draft policy on private prosecutions, as well as what general information regarding breaches of the Veterinary Surgeons Act could be provided to members of the public and the professions.
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life and that the onset of immunity for BRSV is 6 days (for calves vaccinated from the day of birth onwards) and 5 days (for calves vaccinated from the age of one week onwards).
Onset of immunity for Pi3V is one week after vaccination. The duration of immunity is 12 weeks for both viruses.
From a practical standpoint, the new license means Bovilis Intranasal RSP Live can now be used on farm at the same time as other early life interventions associated with newborn calves – for example, colostrum/first milk feeding, navel management, tagging, jacketing and necessary pen movements.
Additionally, Bovilis Intranasal RSP Live can be used up to six hours after mixing with the solvent, which MSD says is the longest of all the available intranasal vaccines for these pathogens.
The vaccine is supplied as a nasal suspension product that doesn’t need a specific applicator – although for maximum flexibility an easy-clean injector and nozzle kit is available for vaccinating multiple animals.
The vaccine is available in 5x1 dose, 5 dose and 5x5 dose packs.
The authors say that the prognosis for dogs with stage II Kiupel high-grade cutaneous mast cell tumours has historically been considered poor.
However, the removal of metastatic regional lymph nodes in more recent research has been associated with a better outcome in canine cutaneous mast cell tumours.
For this study1, dogs with a histological diagnosis of overt lymph node metastasis that underwent lymphadenectomy (n = 31) were compared with those with a cytological diagnosis of regional lymph node metastasis, that did not undergo excision (n 18).
The study was a multi-institutional retrospective cohort study, using electronic medical records from four European institutions to identify dogs for inclusion.
The study found that dogs with Kiupel high-grade cutaneous mast cell tumours undergoing lymphadenectomy of HN3 lymph nodes as part of their primary surgery in addition to adjuvant medical treatment had a significant improvement in time to progression and survival time compared with those dogs not undergoing the procedure.
Lack of lymphadenectomy was the only variable significantly associated with a higher risk of nodal progression.
Dogs underwent lymphadenectomy of one peripheral lymph node in most cases.
The authors says that a higher number of lymph nodes or the removal of intracavitary lymph nodes might be associated with an increased incidence of postoperative morbidity.
They add that the findings warrant further exploration of the effect of surgical extirpation of metastatic sentinel lymph nodes and the number of lymph nodes removed on outcome in dogs with Kiupel high-grade cutaneous mast cell tumours.
Nicola Di Girolamo, Editor of JSAP said: “It is really encouraging to see collaborations from multiple institutions like the study presented here.
"Including multiple institutions in a retrospective cohort study, does not only ensure a higher sample size, but also ensure a higher generalisability of the results.
"Meaning that it is more likely that the differences observed in this study are also going to be observed at different practices and with different clinicians.”
https://onlinelibrary.wiley.com/doi/full/10.1111/jsap.13525
Common ‘Pet Dangers’ include:
The poster also reinforces the importance of S.P.E.E.D when dealing with poisoned pets:
To get your free poster, visit https://www.tvm-uk.com/pet-dangers-order-free-display-materials-for-your-practice/ or email help@tvm-uk.com.
Frontline wormer for cats contains praziquantel and pyrantel embonate, and for dogs it also contains febantel.
According to the company, Frontline Wormer is effective agains all types of intestinal worms found in the UK: roundworms, tapeworms, hookworms and whipworms.
It is presented as a palatable tablet which can be given as a treat without food, or mixed with food.
The press release from the company says the new product "gives pet parents an easy way to worm their cats and dogs".
"Pet parents?"
Someone please pass me the sick bag.
If I get one more press release describing cat or dog owners as 'pet parents", so help me god I will turn up at the press office and chain myself - naked - to the photocopying machine in protest.
It's a ghastly, patronising, cloying way to refer to people who own an animal, besides which, if I really was the parent of a pet, I would expect to be serving time at His Majesty's pleasure.
Frontline Wormer is available in packs of two tablets for 3 pet sizes.
As an AVM-GSL-licensed product, it can be sold off the shelf.
A 2021 German study reported the incidence of diarrhoea to be 18.5% and the most common disease observed in almost 14,000 neonatal calves examined on 731 dairy herds1.
Fencovis is indicated for the active immunisation of pregnant heifers and cows in order to stimulate the development of antibodies against bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin and to increase the level of passive immunity of calves against neonatal diarrhoea caused by bovine rotavirus, bovine coronavirus and E. coli expressing F5 (K99) adhesin.
Boehringer says that in calves fed with colostrum and milk from vaccinated cows, these antibodies have been demonstrated to prevent diarrhoea caused by rotavirus and E. coli F5 (K99) adhesin and reduce the incidence and severity of diarrhoea caused by coronavirus.
Viral shedding in calves infected by rotavirus and coronavirus was also reduced by Fencovis.
Findlay MacBean, Business Head Livestock at Boehringer Ingelheim UK & Ireland, said: “We are delighted to announce the launch of Fencovis, the first vaccine that is licensed to prevent calf scour caused by Rotavirus and E. coli F5 (K99), and also reduce the incidence and severity of scour associated with coronavirus infection. ”
Fencovis is a suspension for injection which uses a non-oil adjuvant. It comes in a variety of presentations including a single dose pack.
Speakers include Prof. Jo Dukes McEwan, Head of Service, Professor in Small Animal Cardiology (University of Liverpool), Doctor Jennifer Schissler, Veterinary Dermatologist, Best Friends Animal Hospital & Urgent Care Unit (US), and Doctor Pascal Prélaud, Dermatologist, CEO ADVETIA Vet Hospital Center (France).
Participants will also be able to access to an immersive experience, the Vet Symposium Village, which includes the Live Stage, Vet Lab, Clinic Lounge, and Innovation Hub, all offering exclusive videos and lectures.
The event will be translated into Chinese, French, Spanish, Italian, Portuguese, Russian, and German, and a replay of the event will be available until the end of the year.
Dr. Jennifer Welser, Chief Medical Officer, Mars Veterinary Health, said: “It’s more critical than ever for pet professionals from various countries, fields, and perspectives to meet and share their knowledge.
"I look forward to participating in the Vet Symposium and speaking with my peers on topics ranging from mental health to advancements in quality medical care and retaining veterinary talent.”
https://digital-vetsymposium2022.com/
He takes over the role from Huw Griffiths at the end of BEVA Congress 7th -10th September 2022. Roger Smith becomes President Elect.
Following graduation from The University of Bristol in 2001, David worked in farm animal and equine practice in Somerset before completing an internship at Liphook Equine Hospital.
A three-year Horserace Betting Levy Board residency at The University of Glasgow and Liphook Equine Hospital enabled him to train as a specialist in equine internal medicine and to gain a masters by research into equine asthma and an RCVS certificate in equine medicine.
David spent several years at Liphook Equine Hospital in Hampshire and had spells at The Royal Veterinary College, London and Charles Sturt University in Australia before moving to Rainbow Equine Hospital in Yorkshire where he led the internal medicine and laboratory services as a director and subsequently a clinical director following the hospital’s acquisition by the VetPartners group.
David returned to his Westcountry roots in 2020 and now combines work as an independent equine medicine and therapeutics consultant with running the family farm on the edge of Exmoor.
He is chair of BEVA’s health and medicines committee.
During his presidential year David is keen to continue build on his recent work around antimicrobial and anthelmintic resistance as well as expanding BEVA’s global outreach to support more equine vets and have a greater impact on equine welfare.
He said: “I’ve had a great time being part of the profession for the past 20 years and I am now in a position to give something back.
“Huw has driven much activity in the past year around recruitment and retention and I hope to be able to build on this and action results from the recent survey, under Huw’s continued supervision. I am also determined to maintain momentum around BEVA’s antimicrobial and anthelmintic resistance work as well as step up collaboration internationally on these and other projects to extend BEVA’s global outreach.
“Around 99% of the world’s horses are cared for by around 1% of the world’s vets so we are not going to change things overnight; however, BEVA has so much to offer and we should use our resources to support equine welfare, irrespective of where equine vets and their patients live and work.”
The online book invites veterinary surgeons to leave written messages of condolence, and pictures.
The book will be available until Monday 3rd October.
Dr Melissa Donald MRCVS, President of the RCVS who will be attending the Queen’s state funeral on behalf of the College, said: “I, along with my colleagues in the Officer Team and on RCVS and VN Councils, were greatly saddened to learn of the death of Her Majesty the Queen last week.
“As our Patron and benefactor since her accession to the throne 70 years ago, as a keen supporter of the veterinary professions who had many interactions with its members, and as an animal-lover, we were keen to give veterinary surgeons and veterinary nurses the opportunity to leave messages of condolence, anecdotes about meeting Her Majesty, and tributes for her many years of duty and service to this country.
“After it closes, we plan to save a digital copy of the online book in the RCVS historical archives for posterity.”
Any nurses who have not received the original email should contact communications@rcvs.org.uk.
Dr Dyson was removed from the Register after she was found to have fabricated a letter from a fictitious Home Office Inspector in support of a paper she had submitted to a journal, explaining why conducting her research had not required a Home Office Licence.
The original Committee made its decision on the basis that her conduct was knowingly dishonest, was likely to bring the profession into disrepute and undermine public confidence in it, and, furthermore, risked undermining the Government’s system designed to promote animal welfare and research ethics.
In considering Dr Dyson’s application for restoration, the Disciplinary Committee took into account a number of factors: her acceptance of the findings of the Committee at the original hearing; the seriousness of the original findings; public protection; risks to animal welfare if she were to be allowed to practise again; the length of time off the Register; her conduct since being removed; her efforts to keep up to date in terms of knowledge, skills and developments in practice; the impact of the sanction on her; and public support for her.
The Committee found that while Dr Dyson had demonstrated some insight into her misconduct, had expressed remorse and admitted dishonesty, it was undermined by her continuing denial that she had been knowingly dishonest in her conduct, having attributed her actions to being in a dissociative state at the time.
In terms of seriousness, the Committee considered that Dr Dyson’s misconduct was at the highest end of the spectrum, having involved being dishonest with multiple people on multiple occasions, and then inventing a fictitious Home Office Inspector to continue the deceit.
The Committee also considered that public confidence in the profession and the RCVS as the regulator would be undermined were Dr Dyson to be allowed to be restored to the Register without genuinely accepting full responsibility for her actions.
In her favour, the Committee considered that there was no risk to the health and welfare of animals and that she had provided ample evidence of her efforts to keep up to date in terms of knowledge, skills and developments in practice should she be allowed to practise again.
In addition, she had made some progress, for example she was able to show some insight by the steps she had taken to avoid finding herself in such a stressful environment in the future. The Committee also considered the many positive testimonials it received from professional colleagues and clients.
Ultimately, however, the Committee decided to refuse Dr Dyson’s application.
Judith Way, chairing the Committee and speaking on its behalf, said: “The Committee considered that public confidence in veterinary surgeons and the profession will not be maintained if a veterinary surgeon who has been found to have committed very serious acts of dishonesty refuses to genuinely accept that that is the case.
“Dr Dyson says that she accepts the original Disciplinary Committee’s finding that she acted dishonestly, but that acceptance carries little weight in light of what she said in her application and has said in her evidence to this Committee, because it involves a theoretical or objective concept of dishonesty which has no bearing upon her actual state of mind at the time of the actions in question.
“By not being truly accountable for her dishonest actions, Dr Dyson has thus far been unable to demonstrate anything other than limited insight into her disgraceful conduct.
“In such circumstances, the Committee considered there would be a real and continuing risk to the reputation of the profession and to public confidence in the profession if Dr Dyson were restored to the Register.
"Conduct of this kind is of a particularly egregious nature for a member of this profession and particularly so of one so eminent in her field and looked up to by so many.
"The Committee was of the view that if a veterinary surgeon, who has committed such serious offences and shown so little insight were nonetheless now allowed to practise, the public’s trust in the profession was liable to be seriously undermined.”